The tissue distributions of FXR and GPBAR1[50, 51] along with their co‐regulatory partners (coactivators and co‐repressors),[52] suggest that their modulation could yield synergistic effects, expanding their pharmacological potential, particularly in complex diseases such as NAFLD and NASH. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.